Spyre Therapeutics doses first subjects in Phase I IBD treatment trial
Spyre Therapeutics has dosed the first subjects in the Phase I clinical trial of SPY001 to potentially treat inflammatory bowel…
Spyre Therapeutics has dosed the first subjects in the Phase I clinical trial of SPY001 to potentially treat inflammatory bowel…
Arcus Biosciences has concluded the subject enrolment in the Phase III STAR-221 clinical trial of domvanalimab plus zimberelimab in combination…
Eupraxia Pharmaceuticals has received approval from regulators in Australia and Canada to expand the Phase I/II RESOLVE clinical trial of…
Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara (ustekinumab) medication in all endoscopic endpoints in a Phase II/III…
Johnson and Johnson (J&J) has announced positive data from the Phase III QUASAR maintenance trial for Tremfya (guselkumab) as a…
Implantica has started the premarket approval process with the US Food and Drug Administration (FDA) for its gastroesophageal reflux disease…
Netherland-based Polpharma Biologics has released topline results from a pharmacokinetic (PK) and pharmacodynamic (PD) study of its biosimilar candidate PB016,…
French biopharmaceutical company, Inventiva has paused recruitment for its pivotal Phase III trial for lanifibranor after a trial participant reported…
Hong Kong-based Insilico Medicine has launched a Phase I trial of its artificial intelligence (AI)-discovered drug ISM5411. The Phase I…
This week on Pipeline Moves, we kick off by looking at Phase III trial terminations by Bayer and Johnson &…